Holen Sie sich die Stockscreener-App
10.26
3.16%
-0.33
Schlusskurs vom Vortag:
$10.59
Offen:
$10.92
24-Stunden-Volumen:
111.03K
Relative Volume:
2.36
Marktkapitalisierung:
$80.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.48M
KGV:
-9.8654
EPS:
-1.04
Netto-Cashflow:
$-28.71M
1W Leistung:
-17.60%
1M Leistung:
+20.79%
6M Leistung:
-52.30%
1J Leistung:
-14.54%
1-Tages-Spanne:
$10.22
$11.20
1-Wochen-Bereich:
$10.22
$19.63
52-Wochen-Spanne:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Firmenname
Forte Biosciences Inc
Sektor
Branche
Telefon
(310) 618-6994
Adresse
3060 PEGASUS PARK DRIVE, DALLAS, CA
Vergleichen Sie FBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
10.25 | 80.65M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.72 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.54 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.85 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.12 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
261.60 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-21 | Eingeleitet | TD Cowen | Buy |
| 2024-04-08 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | Hochstufung | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | Herabstufung | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | Herabstufung | Truist | Buy → Hold |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-26 | Eingeleitet | Citigroup | Buy |
| 2020-08-28 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | Eingeleitet | Truist | Buy |
Alle ansehen
Forte Biosciences Inc Aktie (FBRX) Neueste Nachrichten
Valkyrie Balance Sheet Opportunities ETF (NYSEARCA:VBB) Trading 0.4% Higher – Here’s Why - Defense World
Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
With Forte Biosciences Up 28%, Insider Buyers Count Their Returns - simplywall.st
(FBRX) Long Term Investment Analysis - news.stocktradersdaily.com
Forte Biosciences (FBRX) Receives Buy Rating as FB-102 Shows Blockbuster Potential | FBRX Stock News - GuruFocus
Forte Biosciences reports annual meeting results By Investing.com - Investing.com Nigeria
Forte Biosciences reports annual meeting results - Investing.com
Forte Biosciences Elects New Directors at Annual Meeting - TipRanks
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Top Premarket Decliners - marketscreener.com
Forte Biosciences Reports Increased Losses Amid R&D Expansion - TipRanks
Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Forte Biosciences Q1 Operating Expenses USD 16.124 Million - marketscreener.com
Forte Biosciences (FBRX) Advances Trials for FB102 in Celiac Disease and Vitiligo | FBRX Stock News - GuruFocus
Forte Biosciences reports Q1 EPS ($1.37), consensus (95c) - TipRanks
Forte Biosciences, Inc. Announces Results and Provides Update - Eagle-Tribune
Forte Biosciences Q1: Celiac Disease Trial Results Imminent, New Vitiligo Study Launches - Stock Titan
Stock Traders Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Forte Biosciences (FBRX) Expected to Announce Earnings on Monday - Defense World
JPMorgan Chase & Co. Trims Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World
Royal Bank of Canada Has Lowered Expectations for Zimmer Biomet (NYSE:ZBH) Stock Price - Defense World
JPMorgan Chase & Co. Buys New Holdings in Innovator U.S. Equity Accelerated ETF – January (BATS:XDJA) - Defense World
(FBRX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Geode Capital Management LLC Boosts Stock Position in AmpliTech Group, Inc. (NASDAQ:AMPG) - Defense World
Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Meta Doubles Down on AI: Is the Stock Ready to Skyrocket? - The Globe and Mail
Shining a Light on IL-13: Optimizing Moderate-to-Severe Atopic Dermatitis Treatment in Daily Practice - Healio
Forte Biosciences sets Annual Meeting for May 29 By Investing.com - Investing.com Canada
Forte Biosciences sets Annual Meeting for May 29 - Investing.com Australia
Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World
Mr. Ethan Billings recommends paying close attention to biotech stocks - FinancialContent
Profit from Trump’s Tariff Playbook with TipRanks’ New Comparison Tool - The Globe and Mail
Nvidia and Broadcom Helped Propel This ETF 18% Higher in a Single Day. Here's Why It's Still a Buy Now. - The Globe and Mail
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Analysts Issue Forecasts for FBRX Q2 Earnings - Defense World
Equities Analysts Offer Predictions for FBRX FY2025 Earnings - Defense World
(FBRX) Investment Analysis - news.stocktradersdaily.com
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy - MSN
Forte Biosciences (NASDAQ:FBRX) Given New $61.00 Price Target at Chardan Capital - The AM Reporter
Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World
Chardan Capital Issues Pessimistic Forecast for Forte Biosciences (NASDAQ:FBRX) Stock Price - Defense World
Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating - MarketScreener
Forte Biosciences Reports 2024 Progress and Financials - TipRanks
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Yahoo
Forte's Celiac Treatment Shows Promise: Zero Dropouts and $58.4M War Chest - Stock Titan
Finanzdaten der Forte Biosciences Inc-Aktie (FBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Forte Biosciences Inc-Aktie (FBRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
203,849 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,910,424 |
0.78%
1.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):